证券代码：301256 证券简称：华融化学 公告编号：2025-026 华融化学股份有限公司 第二届董事会第十二次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、董事会会议召开情况 华融化学股份有限公司（以下简称"公司"）第二届董事会第十二次会议通知于 2025年4月17日以电子邮件的形式通知公司全体董事。会议于2025年4月21日9:30在新 希望中鼎国际18楼会议室以现场结合通讯表决方式召开。应出席会议的董事有7名，实 际出席会议的董事有7名（其中，李建雄、张明贵、姚宁、卜新平、刘磊以通讯表决方 式出席会议）。会议由董事长邵军先生主持，公司监事、部分高级管理人员列席了本 次会议。本次会议的召集、召开和表决程序均符合《公司法》等相关法律、行政法规、 部门规章、规范性文件和《公司章程》的规定。会议表决方式为记名投票表决。 二、董事会会议审议情况 1.审议通过《关于<2025年第一季度报告>的议案》； 详见公司同日在巨潮资讯网披露的《关于未来三年（2025年-2027年）股东分红回 报规划的公告》。 表决结果为：同意7票，反对0票，弃权0票。 ...

Revenue and Profit - The company's revenue for Q1 2025 was CNY 385,550,493.62, representing a 57.42% increase compared to CNY 244,924,392.62 in the same period last year[5] - Net profit attributable to shareholders decreased by 26.66% to CNY 15,702,915.91 from CNY 21,411,400.56 year-on-year[5] - Total operating revenue for the current period reached ¥385,550,493.62, a significant increase of 57.3% compared to ¥244,924,392.62 in the previous period[20] - Net profit for the current period was ¥15,702,915.91, a decrease of 26.7% from ¥21,411,400.56 in the previous period[21] - The company experienced a total comprehensive income of ¥15,701,528.20, down from ¥21,411,400.56 in the previous period[21] Cash Flow - The net cash flow from operating activities improved significantly, with a net outflow of CNY -2,643,482.84, a 93.98% increase compared to CNY -43,921,036.88 in the previous year[5] - Cash flow from operating activities showed a net outflow of ¥2,643,482.84, an improvement from a net outflow of ¥43,921,036.88 in the prior period[23] - Cash flow from investing activities generated a net inflow of ¥94,190,963.70, compared to a net outflow of ¥208,209,551.35 in the previous period[23] Assets and Liabilities - Total assets increased by 2.52% to CNY 2,430,901,186.06 from CNY 2,371,260,346.31 at the end of the previous year[5] - The company's total liabilities were CNY 684,218,373.28, compared to CNY 640,223,940.44 at the beginning of the period, marking an increase of about 6.9%[18] - Current assets totaled CNY 2,072,963,270.84, slightly up from CNY 2,027,411,674.04, indicating a growth of about 2.2%[17] - The total non-current assets amounted to CNY 357,937,915.22, up from CNY 343,848,672.27, reflecting a growth of approximately 4.1%[18] Cash and Equivalents - The cash and cash equivalents increased by 135.19%, amounting to a net increase of CNY 85,651,595.93 compared to a net decrease of CNY -243,392,303.05 in the previous year[9] - Cash and cash equivalents at the end of the period totaled ¥386,195,761.97, up from ¥118,768,918.30 at the end of the previous period[24] - Cash and cash equivalents increased to CNY 427,428,592.76 from CNY 310,546,366.47, representing a significant rise of approximately 37.6%[17] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 26,479[10] - The equity attributable to the parent company reached CNY 1,746,682,812.78, up from CNY 1,731,036,405.87, showing a growth of approximately 0.9%[19] Operating Costs and Expenses - The company experienced a 78.72% increase in operating costs, totaling CNY 350,214,583.05 compared to CNY 195,956,053.32 in the same period last year[9] - Total operating costs amounted to ¥370,932,761.05, up 67.0% from ¥222,307,235.73 in the prior period[20] - Research and development expenses decreased to ¥6,090,631.15 from ¥7,960,492.47, reflecting a reduction of 23.5%[20] Earnings Per Share - The company's basic earnings per share decreased by 25.00% to CNY 0.03 from CNY 0.04 year-on-year[5] - Basic and diluted earnings per share were both ¥0.03, down from ¥0.04 in the previous period[21] Investment Income - The company reported a 60.51% increase in investment income, reaching CNY 8,042,803.94 compared to CNY 5,010,661.23 in the same period last year[9] - The company reported an investment income of ¥8,042,803.94, an increase from ¥5,010,661.23 in the prior period[20]

Group 1 - The core point of the article is that Huarong Chemical (301256) reported a revenue of 386 million yuan in the first quarter of 2025, representing a year-on-year increase of 57.42% [1] - The net profit for the same period was 15.7 million yuan, which reflects a year-on-year decrease of 26.66% [1]

华融化学股份有限公司 2024 年年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 特别提示： 一、会议召开和出席情况 1．会议召开情况 华融化学股份有限公司（以下简称"公司"）2024 年年度股东大会于 2025 年 4 月 14 日 15:30 在四川省成都市锦江区金石路 366 号新希望中鼎国际 2 号楼 18 楼会议室 召开。本次股东大会由公司董事会召集，董事长邵军先生主持，会议采用现场表决和 网络投票相结合的方式召开。本次会议召集、召开及表决程序符合有关法律法规和《公 司章程》的规定。 2．会议出席情况 证券代码：301256 证券简称：华融化学 公告编号：2025-0025 1．本次股东大会未出现否决议案的情形。 2．本次股东大会不涉及变更以往股东大会已通过的决议。 | | | 总表决结果 | 358,890,000 | 99.9599 | ％ | 42,600 | 0.0119 | ％ | 101,300 | 0.0282 ％ | 经出席会议有表决 | | --- | --- | --- | --- | --- | --- | ...

北京中伦（成都）律师事务所 关于华融化学股份有限公司 2024 年年度股东大会的 法律意见书 致：华融化学股份有限公司 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共 和国证券法》（以下简称"《证券法》"）、《上市公司股东会规则》（以下简称"《股 东会规则》"）、《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市 公司规范运作》等法律、法规及规范性文件的规定，北京中伦（成都）律师事务 所（以下简称"中伦"或"本所"）指派律师出席了华融化学股份有限公司（以 下简称"公司"）2024 年年度股东大会（以下简称"本次股东大会"），对本次 股东大会的合法性进行见证并出具法律意见。 本所及经办律师依据《证券法》《律师事务所从事证券法律业务管理办法》 和《律师事务所证券法律业务执业规则（试行）》等规定及本法律意见书出具日 以前已经发生或者存在的事实，严格履行了法定职责，遵循了勤勉尽责和诚实信 用原则，进行了充分的核查验证，保证本法律意见所认定的事实真实、准确、完 - 1 - 法律意见书 整，所发表的结论性意见合法、准确，不存在虚假记载、误导性陈述或者重大遗 漏，并承担相应法律责任。为出具本 ...

与此同时，公司还是国内首家采用气体纯化技术生产电子级盐酸的企业，公司利用副产氯化氢气体为原料，原料易得，成本低；工艺流程短，能耗低；生产 过程环保，无低浓度盐酸等副产物产生；装置产能大，可用于不同规格电子级盐酸的生产，产品质量稳定。 华融化学2024年全年实现营业收入12.06亿元，同比增长13.89%，并创出历史新高；其中，当期钾产品实现营收7.42亿元,毛利率31.93%，较上年提升0.88%， 归母净利润10,049.78万元，在化工下行周期下仍实现了较好的经营利润。 在本次活动上，就公司电子化学产品质量等级有关提问，公司方面直言：电子化学品主要依据金属杂质含量、颗粒度和颗粒个数等指标分为G1-G5等级。截 至2024年底，公司2000吨/年的电子级盐酸工业化生产装置已投产，产品品质已达到G5级。 事实上，公司在国内率先进入电子级氢氧化钾、电子级盐酸领域，积累了技术、客户和品牌。 据介绍，公司是国内首家自主开发电子级低钠氢氧化钾技术及成套装置的企业，该技术已实现成果转化并建成投产5000吨/年的工业化生产装置，产出的电 子级低钠氢氧化钾产品，钠含量低于50ppm。 4月11日，华融化学（301256）2 ...

Group 1: Company Performance and Financials - The company achieved a total revenue of 1,206.46 million yuan in 2024, representing a year-on-year growth of 13.89% [8] - Revenue from potassium products reached 742 million yuan, with a gross margin of 31.93%, an increase of 0.88% compared to the previous year [8] - The net profit attributable to the parent company was 100.50 million yuan, demonstrating solid operational profitability despite a downturn in the chemical industry [8] Group 2: Research and Development - In 2024, the company invested 49 million yuan in R&D, accounting for 4.07% of its revenue, positioning it among the leaders in the inorganic salt industry [8] - Cumulative R&D investment from 2022 to 2024 reached 114 million yuan, with an annual compound growth rate of 99.7% [8] - The company focuses on lean production, digital transformation, and chlorination metallurgy as key strategic directions for ongoing R&D [8] Group 3: Strategic Initiatives - The company is implementing the "potassium extension, chlorine transformation" innovation strategy to enhance the quality and sales volume of high-end products [2] - A "cloud factory" platform is being developed to empower small and medium-sized enterprises through a model combining digitalization, supply chain, and technological R&D [3] - The company aims to increase the proportion of high-grade products like electronic-grade potassium hydroxide and hydrochloric acid, targeting the electronics industry [3] Group 4: Market Position and Competitive Advantage - The company has established sales with leading domestic semiconductor clients, leveraging its first-mover and technological advantages in electronic-grade chemicals [6] - It is the first domestic enterprise to develop electronic-grade low-sodium potassium hydroxide technology and to use gas purification technology for producing electronic-grade hydrochloric acid [6] - The company adheres to the "import substitution, self-control" policy, enhancing its competitiveness in the electronic chemicals sector [5] Group 5: Dividend Policy - The company plans to distribute a total cash dividend of 81.60 million yuan for 2024, which represents 81.20% of the distributable profit, with a dividend yield of 2.2% [7] - The profit distribution plan has been approved by the board and awaits shareholder meeting approval [7]

Summary of Key Points Core Viewpoint - The financing balance of the ChiNext market has decreased, with a total balance of 335.18 billion yuan, reflecting a reduction of 10.61 billion yuan compared to the previous period. Despite this, 11 stocks have seen their financing balances increase by over 10%, indicating selective strength within the market [1]. Financing Balance Overview - The total margin financing balance for ChiNext stocks is 336.02 billion yuan, down by 10.6 billion yuan from the previous trading day, marking a continuous decline for three consecutive days [1]. - The margin financing balance specifically stands at 335.18 billion yuan, which is a decrease of 10.61 billion yuan from the previous day [1]. - The margin short-selling balance is 0.841 billion yuan, which has increased by 12.55 million yuan [1]. Stocks with Increased Financing Balances - A total of 130 stocks have seen an increase in their financing balances, with 11 stocks experiencing growth rates exceeding 10%. The stock with the highest increase is Shennong Seed Industry, which has a financing balance of 171.05 million yuan, reflecting a growth of 31.51% and a price increase of 19.95% on the same day [1][3]. - Other notable stocks with significant increases include: - Shibu Testing: 84.41 million yuan, up 30.03% - Yike Food: 73.70 million yuan, up 28.91% - Huarong Chemical: 120.07 million yuan, up 26.84% [3]. Market Performance of Increased Financing Stocks - Stocks with financing balance increases of over 10% averaged a price increase of 9.79% on the same day, with two stocks hitting the daily limit up: Shennong Seed Industry and Huarong Chemical [1]. - Other top performers include Yike Food, with an increase of 11.61%, and Leierwei, with an increase of 10.28% [1]. Stocks with Decreased Financing Balances - A total of 803 stocks have seen a decrease in their financing balances, with 56 stocks experiencing declines of over 10%. The stock with the largest decrease is Hengguang Co., with a financing balance of 65.91 million yuan, down by 27.96% [4]. - Other significant declines include: - Jiuqi Co.: 39.55 million yuan, down 27.87% - Huayang Intelligent: 48.45 million yuan, down 25.02% [4]. Market Performance of Decreased Financing Stocks - The stocks with the largest decreases in financing balances have shown varied market performance, with some experiencing price increases despite the drop in financing [4][5].

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 一、股票交易异常波动的具体情况 华融化学股份有限公司（以下简称"公司"，证券简称"华融化学"，证券代码：301256）股票连续两个交 易日内（2025年4月7日、2025年4月8日）收盘价格涨幅偏离值累计超过30%，根据《深圳证券交易所交 易规则（2023 年修订）》，股票连续三个交易日内日收盘价涨幅偏离值累计达到 30%，属于股票交易 异常波动的情况。 二、公司关注并核实情况的说明 三、是否存在应披露而未披露信息的说明 针对公司股票异常波动的情况，公司董事会通过通讯及问询等方式就相关事项进行了核实，现将有关情 况说明如下： （一）公司前期披露的信息不存在需要更正、补充之处； （二）公司近期经营情况及内外部经营环境未发生重大变化； （三）公司未发现近期公共传媒报道了可能或已经对本公司股票交易价格产生较大影响的未公开重大信 息； （四）公司、控股股东及实际控制人不存在关于本公司的应披露而未披露的重大事项或处于筹划阶段的 重大事项； （五）公司控股股东、实际控制人在股 ...

证券代码：301256 证券简称：华融化学 公告编号：2025-024 华融化学股份有限公司 关于股票交易异常波动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、股票交易异常波动的具体情况 华融化学股份有限公司（以下简称"公司"，证券简称"华融化学"，证券 代码：301256）股票连续两个交易日内（2025 年 4 月 7 日、2025 年 4 月 8 日） 收盘价格涨幅偏离值累计超过 30%，根据《深圳证券交易所交易规则（2023 年 修订）》，股票连续三个交易日内日收盘价涨幅偏离值累计达到 30%，属于股票 交易异常波动的情况。 （五）公司控股股东、实际控制人在股票异常波动期间不存在买卖公司股票 的行为。 三、是否存在应披露而未披露信息的说明 公司董事会确认，公司目前没有任何根据《深圳证券交易所创业板股票上市 规则》等有关规定应予以披露而未披露的事项或与该事项有关的筹划、商谈、意 1 向、协议等；董事会也未获悉公司有根据《深圳证券交易所创业板股票上市规则》 等有关规定应予以披露而未披露的、对公司股票价格产生较大影响的信息；公司 前期披露的信息不 ...